Core Viewpoint - Rosen Law Firm is reminding investors who purchased Unicycive Therapeutics, Inc. securities during the specified class period of the upcoming lead plaintiff deadline on October 14, 2025 [1]. Group 1: Class Action Details - Investors who bought Unicycive securities between March 29, 2024, and June 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit claims that Unicycive made false or misleading statements regarding its compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application [5]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking highly in annual securities class action settlements since 2013 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Unicycive Therapeutics, Inc. securities during the specified class period of the upcoming lead plaintiff deadline on October 14, 2025 [1]. Group 1: Class Action Details - Investors who bought Unicycive securities between March 29, 2024, and June 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm or visiting their website [3][6]. - The lead plaintiff must file a motion with the court by October 14, 2025, to represent other class members in the litigation [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4]. Group 3: Case Allegations - The lawsuit alleges that Unicycive made false or misleading statements regarding its ability to meet FDA manufacturing compliance requirements and the regulatory prospects of its New Drug Application for oxylanthanum carbunate [5]. - The claims suggest that these misrepresentations led to investor damages when the true information became public [5].

Core Viewpoint - Fly-E Group, Inc. is facing a class action lawsuit due to significant financial losses and misleading statements made by the company's management regarding its business operations and prospects during the class period from July 15, 2025, to August 14, 2025 [1][3]. Financial Performance - On August 14, 2025, Fly-E reported a 32% year-over-year decline in net revenues, primarily attributed to decreased unit sales following multiple lithium-battery accidents involving its E-Bikes and E-Scooters [2]. - Following this announcement, Fly-E's stock price plummeted by $6.76, or 87.1%, closing at $1.00 per share on August 15, 2025, resulting in significant losses for investors [2]. Lawsuit Details - The class action lawsuit alleges that Fly-E's management made materially false and misleading statements and failed to disclose adverse facts about the company's business and operations [3]. - Specifically, the lawsuit claims that management downplayed risks associated with lithium batteries, supply chain changes, regulatory environments, and demand fluctuations for its products while promoting the company's brand reputation and cost reductions as key growth factors [3]. Legal Actions - Investors who purchased Fly-E securities during the class period have until November 7, 2025, to file a lead plaintiff motion in the class action lawsuit [4].

Group 1 - The article highlights the upcoming deadline of November 20, 2025, for investors to file a lead plaintiff motion in a class action lawsuit concerning RCI Hospitality Holdings, Inc. [1] - The class action is on behalf of investors who purchased or acquired RCI securities between December 15, 2021, and September 16, 2025, inclusive [1] - The notice serves as a reminder for investors who suffered losses on their RCI investments to inquire about potentially pursuing the case [1]

Group 1 - The article highlights the upcoming deadline of November 18, 2025, for investors to file a lead plaintiff motion in a securities fraud lawsuit related to KBR, Inc. [1] - The lawsuit is on behalf of investors who purchased KBR securities between May 6, 2025, and June 19, 2025, indicating a specific class period for the claims [1] - Investors who suffered losses in KBR, Inc. are encouraged to contact the Law Offices of Howard G. Smith to participate in the ongoing lawsuit [1]

Core Viewpoint - Quanex Building Products Corporation is facing a class action lawsuit due to significant operational issues in its Tyman facility in Mexico, which have adversely affected its financial performance and misled investors about the company's operational health [1][4]. Financial Performance - For Q3 2025, Quanex reported a diluted EPS of ($6.04), a significant decline from $0.77 in the same period the previous year [2]. - The adjusted EBITDA for the same quarter was reported at $70.30 million [2]. - The operational challenges in the Tyman facility negatively impacted EBITDA in the Hardware Solutions segment by almost $5 million during Q3 2025 [3]. Stock Market Reaction - Following the announcement of the financial results, Quanex's stock price fell by $2.73, or 13.1%, closing at $18.18 per share on September 5, 2025 [3]. - The stock continued to decline, dropping an additional $1.98, or 10.9%, to close at $16.20 per share on September 8, 2025 [3]. Lawsuit Details - The class action lawsuit alleges that the company made materially false and misleading statements regarding its business operations and failed to disclose significant operational issues in the Tyman facility [4]. - Specific allegations include underinvestment in tooling and equipment maintenance, leading to degraded conditions and increased costs, which were not communicated to investors [4]. Legal Action Timeline - Investors who purchased Quanex securities during the class period (December 12, 2024, to September 5, 2025) have until November 18, 2025, to file a lead plaintiff motion in the class action lawsuit [1][5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Spectrum Pharmaceuticals, Inc. during the specified class period of the upcoming lead plaintiff deadline on September 24, 2025 [1]. Group 1: Class Action Details - Investors who bought Spectrum Pharmaceuticals common stock between May 12, 2022, and September 22, 2022, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][5]. - The lawsuit alleges that Spectrum made false or misleading statements regarding its PINNACLE Study related to the drug poziotinib, which impacted investors when the true details were revealed [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4]. Group 3: Class Certification Status - No class has been certified yet, meaning investors are not represented by counsel unless they retain one, and they can choose to remain absent from the class [6].

Core Viewpoint - A lawsuit has been filed against Charter Communications, Inc. and certain senior executives for potential violations of federal securities laws, particularly related to the impact of the Affordable Connectivity Program's termination on the company's customer base and earnings [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Sandoval v. Charter Communications, Inc., No. 1:25-cv-06747, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until October 14, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - Charter is a leading broadband and cable operator that participated in the FCC's Affordable Connectivity Program (ACP), which provided funding to subsidize high-speed internet plans for low-income households [3]. - The ACP ended in June 2024 due to a lack of federal funding, leading to customer declines for Charter [3]. Group 3: Financial Impact - During the relevant period, Charter claimed to have successfully managed the risks associated with the end of the ACP, stating that the impact was behind them [4]. - However, the company continued to experience declines in internet customers and revenue due to the program's termination [4]. - In Q2 2025, Charter reported a decrease of 117,000 total internet customers, including approximately 50,000 disconnects related to the ACP's end, nearly double the disconnects from the previous quarter [5]. - Following this announcement, Charter's stock price fell by $70.25 per share, or 18.4%, from $380.00 on July 24, 2025, to $309.75 on July 25, 2025 [5].

Core Viewpoint - Replimune Group, Inc. is facing a securities fraud lawsuit following significant stock price declines due to regulatory setbacks and alleged misleading statements regarding its clinical trials [1][3]. Group 1: Stock Performance and Regulatory Issues - Replimune's stock plummeted over 70% on July 22 after receiving a Complete Response Letter (CRL) from the FDA, which rejected its application for an advanced melanoma therapy due to insufficient clinical evidence from a Phase 2 study [2]. - The stock experienced another decline of over 40% on September 18 after a Type A meeting with the FDA, leaving the path forward under the accelerated approval pathway uncertain [2]. Group 2: Legal Actions and Investor Eligibility - A complaint has been filed against Replimune, alleging that the company made materially false and misleading statements about its IGNYTE clinical trial and the prospects for regulatory approval of its treatment [3]. - Investors who purchased Replimune common stock between November 22, 2024, and July 21, 2025, and have experienced losses may be eligible to participate in the lawsuit [4]. Group 3: Next Steps for Investors - The deadline for investors to seek appointment as lead plaintiff is September 22, 2025, and a class has not yet been certified [5]. - Investors are encouraged to contact Block & Leviton for more information on how to proceed if they have lost money on their investment [5]. Group 4: Whistleblower Information - Individuals with non-public information about Replimune are encouraged to assist in the investigation or file a report with the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [6]. Group 5: Firm Background - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Core Viewpoint - PubMatic, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its business operations and a significant reduction in ad spend from a top demand-side platform (DSP) partner, which negatively impacted its stock price [2][3]. Group 1: Company Financial Performance - On August 11, 2025, PubMatic released its Q2 2025 financial report, revealing a reduction in ad spend from one of its top DSP partners [2]. - The stock price of PubMatic fell by $2.23, or 21.1%, closing at $8.34 per share on August 12, 2025, following the financial report [2]. Group 2: Lawsuit Details - The class action lawsuit alleges that during the Class Period, PubMatic's executives made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects [3]. - Specific allegations include the failure to disclose the shift of clients to a new platform by a top DSP buyer, resulting in reduced ad spend and revenue for PubMatic [3]. Group 3: Legal Actions - Investors who purchased PubMatic securities during the Class Period can file a lead plaintiff motion by October 20, 2025, to participate in the class action lawsuit [4].